Double-Blind, Randomized, Vehicle-Controlled Proof of Concept Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal (SEB) Cell Carcinomas in Gorlin Syndrome Patients

Trial Profile

Double-Blind, Randomized, Vehicle-Controlled Proof of Concept Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal (SEB) Cell Carcinomas in Gorlin Syndrome Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs Patidegib (Primary)
  • Indications Basal cell nevus syndrome
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors PellePharm
  • Most Recent Events

    • 20 Nov 2017 According to a PellePharm media release, based on the data from this study, U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to topical patidegib for the treatment of Basal Cell Carcinoma Nevus Syndrome (BCCNS).
    • 31 Jul 2017 Top-line results published in a PellePharm Media Release.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top